Alumis Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Alumis Inc.
- Former names
- FL2021-001, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- South SAN Francisco
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- ALMS
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001847367
Board of directors
-
Alan Colowick · DirectorSince 2024
-
David E. Goel · DirectorSince 2024
-
James B. Tananbaum · DirectorSince 2024
-
Lynn A. Tetrault · DirectorSince 2025
-
Martin Babler · Director · President, CEO and ChairmanSince 2024
-
Patrick Machado · DirectorSince 2024
-
Sapna Srivastava · DirectorSince 2024
- Since 2024
-
Zhengbin Yao · DirectorSince 2024
Chief executives
Martin Babler
· President, CEO and Chairman
Dates unknown
Director election results
Annual meeting of July 30, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
86.8%
-
87.7%
Board connections
8 of this board's directors also sit on 17 other boards.
- via Patrick Machado
- via Zhengbin Yao
- via Sapna Srivastava
- via Sapna Srivastava
- via Srinivas Akkaraju
- via James B. Tananbaum
- via Martin Babler
- via Alan Colowick
- via Srinivas Akkaraju
- via Lynn A. Tetrault
- via Martin Babler
- via Alan Colowick
- via Martin Babler
- via Lynn A. Tetrault
- via Srinivas Akkaraju
- via Patrick Machado
- via Srinivas Akkaraju
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $61,678,655
- 40 purchases by 6 insiders
- Sold, last 12 months
- $1,548,339
- 9 sales by 7 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Srinivas Akkaraju Director | Open-market sale | −48,066 | $10.55 | $507,019 |
| Sep 8, 2026 | Srinivas Akkaraju Director | Open-market sale | −48,065 | $10.55 | $507,009 |
| Sep 8, 2026 | Srinivas Akkaraju Director | Open-market purchase | +273,291 | $10.63 | $2,904,291 |
| Sep 8, 2026 | Srinivas Akkaraju Director | Open-market purchase | +273,290 | $10.63 | $2,904,280 |
| Sep 4, 2026 | Srinivas Akkaraju Director | Open-market purchase | +220,070 | $11.17 | $2,458,842 |
| Sep 4, 2026 | Srinivas Akkaraju Director | Open-market purchase | +220,070 | $11.17 | $2,458,842 |
| Aug 3, 2026 | Hardiman Roy C. Officer (Chief Business & Strategy Ofcr) | Open-market sale | −2,692 | $26.37 | $70,988 |
| Aug 3, 2026 | John R. Schroer Officer (Chief Financial Officer) | Open-market sale | −3,282 | $26.37 | $86,546 |
| Aug 3, 2026 | Goldstein David M Officer (Chief Scientific Officer) | Open-market sale | −2,596 | $26.37 | $68,457 |
| Aug 3, 2026 | Drappa Jorn Officer (Chief Medical Officer) | Open-market sale | −2,447 | $26.37 | $64,527 |
| Aug 3, 2026 | Bradley Mark Christopher Officer (Chief Development Officer) | Open-market sale | −2,572 | $26.37 | $67,824 |
| Aug 3, 2026 | Pangali Sanam Officer (Chief Legal Officer) | Open-market sale | −1,364 | $26.37 | $35,969 |
| Jul 6, 2026 | Pangali Sanam Officer (Chief Legal Officer) | Option exercise | +5,000 | $5.06 | $25,300 |
| Jul 6, 2026 | Pangali Sanam Officer (Chief Legal Officer) | Open-market sale | −5,000 | $28.00 | $140,000 |
| Jun 30, 2026 | Srinivas Akkaraju Director | Grant or award | +3,553 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.